The RalGEF-ral effector signaling network: The road less traveled for anti-ras drug discovery

Genes and Cancer

Volumn 2, Issue 3, 2011, Pages 275-287

  Neel, Nicole F ^a   Martin, Timothy D ^b   Stratford, Jeran K ^b   Zand, Tanya P ^b   Reiner, David J ^a,b   Der, Channing J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aurora A; Exocyst complex; Geranylgeranyltransferase i inhibitor; RalBP1 RLIP76

Indexed keywords

ANTINEOPLASTIC AGENT; GGTI 2418; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C; RAF PROTEIN; RAL PROTEIN; RAS PROTEIN; RAS PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BLADDER CANCER; CAENORHABDITIS ELEGANS; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; COLORECTAL CANCER; DROSOPHILA MELANOGASTER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR EVOLUTION; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 79960069763     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911407329     Document Type: Review

References (143)

1. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517-31.
2. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases. 2010;1:1-27.
3. Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets. 2007;11:673-94.
4. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta. 2008;1786:178-87.
5. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 2004;14:639-47.
6. Young A, Lyons J, Miller AL, Phan VT, Alarcon IR, McCormick F. Ras signaling and therapies. Adv Cancer Res. 2009;102:1-17.
7. Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer. 2006;119:2261-71.
8. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5:875-85.
9. Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol. 2010;346:143-69.
10. Vogt PK, Gymnopoulos M, Hart JR. PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev. 2009;19:12-7.
11. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20:87-90.
12. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer. 2008;8:133-40.
13. Chardin P, Tavitian A. The ral gene: a new ras related gene isolated by the use of a synthetic probe. EMBO J. 1986;5:2203-8.
14. Chardin P, Tavitian A. Coding sequences of human ralA and ralB cDNAs. Nucleic Acids Res. 1989;17:4380.
15. Albright CF, Giddings BW, Liu J, Vito M, Weinberg RA. Characterization of a guanine nucleotide dissociation stimulator for a rasrelated GTPase. EMBO J. 1993;12:339-47.
16. Vojtek AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell. 1993;74:205-14.
17. Hofer F, Fields S, Schneider C, Martin GS. Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. Proc Natl Acad Sci U S A. 1994;91:11089-93.
18. Spaargaren M, Bischoff JR. Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap. Proc Natl Acad Sci U S A. 1994;91:12609-13.
19. Lopez-Barahona M, Bustelo XR, Barbacid M. The TC21 oncoprotein interacts with the Ral guanosine nucleotide dissociation factor. Oncogene. 1996;12:463-70.
20. Kikuchi A, Demo SD, Ye ZH, Chen YW, Williams LT. ralGDS family members interact with the effector loop of ras p21. Mol Cell Biol. 1994;14:7483-91.
21. Peterson SN, Trabalzini L, Brtva TR, et al. Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1. J Biol Chem. 1996;271:29903-8.
22. Wolthuis RM, Bauer B, van't Veer LJ, et al. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein. Oncogene. 1996;13: 353-62.
23. Shao H, Andres DA. A novel RalGEF-like protein, RGL3, as a candidate effector for rit and Ras. J Biol Chem. 2000;275:26914-24.
24. Xu J, Shi S, Matsumoto N, Noda M, Kitayama H. Identification of Rgl3 as a potential binding partner for Rap-family small G-proteins and profilin II. Cell Signal. 2007;19:1575-82.
25. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol. 2004;24:4943-54.
26. Murphy GA, Graham SM, Morita S, et al. Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation. J Biol Chem. 2002;277:9966-75.
27. Ferro E, Trabalzini L. RalGDS family members couple Ras to Ral signalling and that's not all. Cell Signal. 2010;22:1804-10.
28. Mirey G, Balakireva M, L'Hoste S, Rosse C, Voegeling S, Camonis J. A Ral guanine exchange factor-Ral pathway is conserved in Drosophila melanogaster and sheds new light on the connectivity of the Ral, Ras, and Rap pathways. Mol Cell Biol. 2003;23:1112-24.
29. Zand TP, Reiner DJ, Der CJ. Ras effector switching promotes divergent cell fates in C. elegans vulva patterning. Dev Cell. 2011;20:84-96.
30. Ceriani M, Scandiuzzi C, Amigoni L, Tisi R, Berruti G, Martegani E. Functional analysis of RalGPS2, a murine guanine nucleotide exchange factor for RalA GTPase. Exp Cell Res. 2007;313:2293-307.
31. de Bruyn KM, de Rooij J, Wolthuis RM, et al. RalGEF2, a pleckstrin homology domain containing guanine nucleotide exchange factor for Ral. J Biol Chem. 2000;275:29761-6.
32. Martegani E, Ceriani M, Tisi R, Berruti G. Cloning and characterization of a new Ral-GEF expressed in mouse testis. Ann N Y Acad Sci. 2002;973:135-7.
33. Rebhun JF, Chen H, Quilliam LA. Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral. J Biol Chem. 2000;275:13406-10.
34. D'Adamo DR, Novick S, Kahn JM, Leonardi P, Pellicer A. rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral. Oncogene. 1997;14:1295-305.
35. Hernandez-Munoz I, Malumbres M, Leonardi P, Pellicer A. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways. Oncogene. 2000;19:2745-57.
36. Shirakawa R, Fukai S, Kawato M, et al. Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases. J Biol Chem. 2009;284:21580-8.
37. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10:842-57.
38. Cantor SB, Urano T, Feig LA. Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol Cell Biol. 1995;15:4578-84.
39. Jullien-Flores V, Dorseuil O, Romero F, et al. Bridging Ral GTPase to Rho pathways: RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem. 1995;270:22473-7.
40. Park SH, Weinberg RA. A putative effector of Ral has homology to Rho/Rac GTPase activating proteins. Oncogene. 1995;11:2349-55.
41. Fenwick RB, Campbell LJ, Rajasekar K, et al. The RalB-RLIP76 complex reveals a novel mode of ral-effector interaction. Structure. 2010;18:985-95.
42. Matsubara K, Hinoi T, Koyama S, Kikuchi A. The post-translational modifications of Ral and Rac1 are important for the action of Ral-binding protein 1, a putative effector protein of Ral. FEBS Lett. 1997;410:169-74.
43. Ikeda M, Ishida O, Hinoi T, Kishida S, Kikuchi A. Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. J Biol Chem. 1998;273:814-21.
44. Yamaguchi A, Urano T, Goi T, Feig LA. An Eps homology (EH) domain protein that binds to the Ral-GTPase target, RalBP1. J Biol Chem. 1997;272:31230-4.
45. Cullis DN, Philip B, Baleja JD, Feig LA. Rab11- FIP2, an adaptor protein connecting cellular components involved in internalization and recycling of epidermal growth factor receptors. J Biol Chem. 2002;277:49158-66.
46. Morinaka K, Koyama S, Nakashima S, et al. Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis. Oncogene. 1999;18:5915-22.
47. Nakashima S, Morinaka K, Koyama S, et al. Small G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors. EMBO J. 1999;18:3629-42.
48. Jullien-Flores V, Mahe Y, Mirey G, et al. RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis. J Cell Sci. 2000;113(Pt 16):2837-44.
49. Matsuzaki T, Hanai S, Kishi H, et al. Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ralbinding protein 1-dependent pathway. J Biol Chem. 2002;277:19008-18.
50. Hu Y, Mivechi NF. HSF-1 interacts with Ralbinding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo. J Biol Chem. 2003;278:17299-306.
51. Rosse C, L'Hoste S, Offner N, Picard A, Camonis J. RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J Biol Chem. 2003;278:30597-604.
52. Han K, Kim MH, Seeburg D, et al. Regulated RalBP1 binding to RalA and PSD-95 controls AMPA receptor endocytosis and LTD. PLoS Biol. 2009;7:e1000187.
53. Awasthi S, Cheng J, Singhal SS, et al. Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry. 2000;39:9327-34.
54. Awasthi S, Cheng JZ, Singhal SS, et al. Functional reassembly of ATP-dependent xenobiotic transport by the N- and C-terminal domains of RLIP76 and identification of ATP binding sequences. Biochemistry. 2001;40: 4159-68.
55. Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS. RLIP76: a versatile transporter and an emerging target for cancer therapy. Biochem Pharmacol. 2010;79:1699-705.
56. Moskalenko S, Henry DO, Rosse C, Mirey G, Camonis JH, White MA. The exocyst is a Ral effector complex. Nat Cell Biol. 2002;4:66-72.
57. Moskalenko S, Tong C, Rosse C, et al. Ral GTPases regulate exocyst assembly through dual subunit interactions. J Biol Chem. 2003;278:51743-8.
58. Wu H, Rossi G, Brennwald P. The ghost in the machine: small GTPases as spatial regulators of exocytosis. Trends Cell Biol. 2008;18:397-404.
59. He B, Guo W. The exocyst complex in polarized exocytosis. Curr Opin Cell Biol. 2009;21:537-42.
60. Spiczka KS, Yeaman C. Ral-regulated interaction between Sec5 and paxillin targets exocyst to focal complexes during cell migration. J Cell Sci. 2008;121:2880-91.
61. Ohta Y, Suzuki N, Nakamura S, Hartwig JH, Stossel TP. The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci U S A. 1999;96:2122-8.
62. Sidhu RS, Clough RR, Bhullar RP. Regulation of phospholipase C-delta1 through direct interactions with the small GTPase Ral and calmodulin. J Biol Chem. 2005;280:21933-41.
63. Luo JQ, Liu X, Hammond SM, et al. RalA interacts directly with the Arf-responsive, PIP2- dependent phospholipase D1. Biochem Biophys Res Commun. 1997;235:854-9.
64. Xu L, Frankel P, Jackson D, et al. Elevated phospholipase D activity in H-Ras- but not K-Rastransformed cells by the synergistic action of RalA and ARF6. Mol Cell Biol. 2003;23:645-54.
65. Shipitsin M, Feig LA. RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells. Mol Cell Biol. 2004;24:5746-56.
66. Lim KH, Brady DC, Kashatus DF, et al. Aurora- A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol. 2010;30:508-23.
67. Cascone I, Selimoglu R, Ozdemir C, et al. Distinct roles of RalA and RalB in the progression of cytokinesis are supported by distinct RalGEFs. EMBO J. 2008;27:2375-87.
68. de Ruiter ND, Wolthuis RM, van Dam H, Burgering BM, Bos JL. Ras-dependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway. Mol Cell Biol. 2000;20:8480-8.
69. Okan E, Drewett V, Shaw PE, Jones P. The small- GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism. Oncogene. 2001;20:1816-24.
70. Goi T, Shipitsin M, Lu Z, Foster DA, Klinz SG, Feig LA. An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J. 2000;19:623-30.
71. de Gorter DJ, Vos JC, Pals ST, Spaargaren M. The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral. J Immunol. 2007;178:1405-14.
72. De Ruiter ND, Burgering BM, Bos JL. Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451. Mol Cell Biol. 2001;21:8225-35.
73. Okazaki M, Kishida S, Hinoi T, et al. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator. Oncogene. 1997;14:515-21.
74. Wolthuis RM, de Ruiter ND, Cool RH, Bos JL. Stimulation of gene induction and cell growth by the Ras effector Rlf. EMBO J. 1997;16:6748-61.
75. Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell. 2006;127: 157-70.
76. Henry DO, Moskalenko SA, Kaur KJ, et al. Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol Cell Biol. 2000;20:8084-92.
77. Oxford G, Smith SC, Hampton G, Theodorescu D. Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector. Oncogene. 2007;26:7143-52.
78. Harris J, Oliere S, Sharma S, et al. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon. J Immunol. 2006;177:2527-35.
79. Smith SC, Oxford G, Baras AS, et al. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin Cancer Res. 2007;13:3803-13.
80. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/Pselectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000;60:6714-22.
81. Urano T, Emkey R, Feig LA. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J. 1996;15:810-6.
82. White MA, Vale T, Camonis JH, Schaefer E, Wigler MH. A role for the Ral guanine nucleotide dissociation stimulator in mediating Rasinduced transformation. J Biol Chem. 1996;271: 16439-42.
83. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 2002; 16:2045-57.
84. Joneson T, White MA, Wigler MH, Bar-Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science. 1996;271:810-2.
85. Khosravi-Far R, White MA, Westwick JK, et al. Oncogenic Ras activation of Raf/mitogenactivated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol. 1996;16:3923-33.
86. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89:457-67.
87. White MA, Nicolette C, Minden A, et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 1995;80:533-41.
88. Chien Y, White MA. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep. 2003;4:800-6.
89. Gonzalez-Garcia A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell. 2005;7:219-26.
90. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549-54.
91. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-6.
92. Lim KH, O'Hayer K, Adam SJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol. 2006;16:2385-94.
93. Vigil D, Martin TD, Williams F, Yeh JJ, Campbell SL, Der CJ. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ralindependent mechanisms. J Biol Chem. 2010;285: 34729-40.
94. Balasubramanian N, Meier JA, Scott DW, Norambuena A, White MA, Schwartz MA. RalA-exocyst complex regulates integrindependent membrane raft exocytosis and growth signaling. Curr Biol. 2010;20:75-9.
95. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268-74.
96. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108-13.
97. Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res. 2011;71:206-15.
98. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 2005;7:533-45.
99. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-12.
100. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
101. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122: 337-41.
102. Bervoets K, Millan MJ, Colpaert FC. Agonist action at 5-HT1C receptors facilitates 5-HT1A receptor-mediated spontaneous tail-flicks in the rat. Eur J Pharmacol. 1990;191:185-95.
103. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
104. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
105. Omholt K, Hansson J. No evidence of RALGDS mutations in cutaneous melanoma. Melanoma Res. 2007;17:410-2.
106. Mishra PJ, Ha L, Rieker J, et al. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene. 2010;29:2449-56.
107. Zipfel PA, Brady DC, Kashatus DF, Ancrile BD, Tyler DS, Counter CM. Ral activation promotes melanomagenesis. Oncogene. 2010;29: 4859-64.
108. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008-17.
109. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24:5218-25.
110. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.
111. Oxford G, Owens CR, Titus BJ, et al. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res. 2005;65:7111-20.
112. Shi M, Zheng Y, Garcia A, Xu L, Foster DA. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007;258:268-75.
113. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393-406.
114. Rinaldo F, Li J, Wang E, Muders M, Datta K. RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. Oncogene. 2007;26:1731-8.
115. Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, Datta K. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res. 2008;68:8770-8.
116. Oosterhoff JK, Penninkhof F, Brinkmann AO, Anton Grootegoed J, Blok LJ. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene. 2003;22:2920-5.
117. Yin J, Pollock C, Tracy K, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007;27:7538-50.
118. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151:33-40.
119. Bodempudi V, Yamoutpoor F, Pan W, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol. 2009;29:3964-74.
120. de Gorter DJ, Reijmers RM, Beuling EA, et al. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood. 2008;111:3364-72.
121. Yu Y, Feig LA. Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells. Oncogene. 2002;21: 7557-68.
122. Li TT, Alemayehu M, Aziziyeh AI, et al. Betaarrestin/ Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res. 2009;7:1064-77.
123. Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA. RalA suppresses early stages of Ras-induced squamous cell carcinoma progression. Oncogene. 2010;29:45-55.
124. Fortini ME, Simon MA, Rubin GM. Signalling by the sevenless protein tyrosine kinase is mimicked by Ras1 activation. Nature. 1992;355:559-61.
125. Han M, Sternberg PW. let-60, a gene that specifies cell fates during C. elegans vulval induction, encodes a ras protein. Cell. 1990;63:921-31.
126. Dickson B, Sprenger F, Morrison D, Hafen E. Raf functions downstream of Ras1 in the Sevenless signal transduction pathway. Nature. 1992;360:600-3.
127. Balakireva M, Rosse C, Langevin J, et al. The Ral/ exocyst effector complex counters c-Jun N-terminal kinase-dependent apoptosis in Drosophila melanogaster. Mol Cell Biol. 2006;26:8953-63.
128. Ghiglione C, Devergne O, Cerezo D, Noselli S. Drosophila RalA is essential for the maintenance of Jak/Stat signalling in ovarian follicles. EMBO Rep. 2008;9:676-82.
129. Frische EW, Pellis-van Berkel W, van Haaften G, et al. RAP-1 and the RAL-1/exocyst pathway coordinate hypodermal cell organization in Caenorhabditis elegans. EMBO J. 2007;26:5083-92.
130. Han M, Golden A, Han Y, Sternberg PW. C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation. Nature. 1993;363:133-40.
131. Berset T, Hoier EF, Battu G, Canevascini S, Hajnal A. Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 during C. elegans vulval development. Science. 2001;291:1055-8.
132. Sundaram MV. The love-hate relationship between Ras and Notch. Genes Dev. 2005;19:1825-39.
133. Reid TS, Terry KL, Casey PJ, Beese LS. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol. 2004;343:417-33.
134. Kinsella BT, Erdman RA, Maltese WA. Carboxyl-terminal isoprenylation of ras-related GTP-binding proteins encoded by rac1, rac2, and ralA. J Biol Chem. 1991;266:9786-94.
135. Falsetti SC, Wang DA, Peng H, et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorageindependent growth. Mol Cell Biol. 2007;27: 8003-14.
136. Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther. 2009;8:1218-26.
137. Liu M, Sjogren AK, Karlsson C, et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci U S A. 2010;107:6471-6.
138. Sjogren AK, Andersson KM, Khan O, Olofsson FJ, Karlsson C, Bergo MO. Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RAS-induced myeloproliferative disease. Leukemia. 2011;25:186-9.
139. Bivona TG, Quatela SE, Bodemann BO, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl- XL on mitochondria and induces apoptosis. Mol Cell. 2006;21:481-93.
140. Wu JC, Chen TY, Yu CT, et al. Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J Biol Chem. 2005;280:9013-22.
141. Sablina AA, Chen W, Arroyo JD, et al. The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 2007;129:969-82.
142. Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res. 2010;70:8760-9.
143. Feldmann G, Mishra A, Hong SM, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010;70:4460-9.